<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796079</url>
  </required_header>
  <id_info>
    <org_study_id>ThirdSouthernMedical</org_study_id>
    <nct_id>NCT02796079</nct_id>
  </id_info>
  <brief_title>A Clinical Study Using Autologous Bone Marrow Stem Cell for Diabetes Related Vascular Complications</brief_title>
  <official_title>A Clinical Study Using Autologous Bone Marrow Stem Cell for Diabetes Related Vascular Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jie Shen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academy Military Medical Science, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fifth Affiliated Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Third Affiliated Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stem cell therapy has been a new and effective therapy in recent years for diabetic foot.This
      study intends to establish an optimal clinical research program, and attempts to break the
      technical bottleneck in the stem cell therapy for treating diabetes related vascular
      complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic foot is one of the most serious chronic complications of diabetic patients, and
      still lacking effective treatments.

      Stem cell therapy has been a new and effective therapy in recent years for diabetic foot.
      Combined with the previous studies of our research group, this study intends to transform
      part of the results of this research, establish an optimal clinical research program, and
      attempts to break the technical bottleneck in the stem cell therapy for treating diabetes
      related vascular complications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area of diabetic foot ulcers</measure>
    <time_frame>3 months</time_frame>
    <description>To determine the ability of MSC to facilitate and accelerate diabetic foot ulcers healing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of transcutaneous oxygen partial pressure (TcPO2)</measure>
    <time_frame>3 months</time_frame>
    <description>Improvement of local perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of microvascular cutaneous reactivity by laser Doppler perfusion monitoring (LDPM)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain (Visual-Analog Scale)</measure>
    <time_frame>3 months</time_frame>
    <description>Measure of the subjective symptom of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking distance (treadmill) if possible</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Ischemia</condition>
  <condition>Diabetic Foot</condition>
  <arm_group>
    <arm_group_label>Autologous Bone Marrow Stem Cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesenchymal stem cells derived from bone marrow infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cells</intervention_name>
    <description>stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell</description>
    <arm_group_label>Autologous Bone Marrow Stem Cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>saline injections</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus Type 2 or Type 1

          -  Age between 18-80 years

          -  Chronic foot ulcer more than 6 weeks

          -  No sufficient response to best standard care delivered for six weeks.

          -  PAD up to Fontaine stage III or IV period

          -  CLI with the ankle brachial index (index ankle-brachial, ABI) &lt;0.7 and (or) the
             percutaneous oxygen partial pressure (oxygen tension transcutaneous, TcPO2) &lt;30mmHg

        Exclusion Criteria:

          -  HbA1c &gt;12%

          -  Hemoglobin &lt;10 mg/dl

          -  Creatinine clearance rate &lt;30ml/min

          -  Systemic bacterial, viral infections (Mei Du, hepatitis, cytomegalovirus infection,
             HIV, B19 infection, herpes virus infection) and sepsis

          -  Have accepted the treatment of stem cells or growth factors

          -  Have a history of malignant disease

          -  Pregnancy

          -  Mental illness history

          -  Abnormal coagulation function

          -  Allergic reaction

          -  Severe cardiac insufficiency (III-IV NYHA)

          -  Using vasoactive substances
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Affiliated Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Shen</last_name>
    <phone>+86 13808893818</phone>
    <email>shenjiedr@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Third Affiliated Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Qun</last_name>
      <phone>020-62784060</phone>
      <email>Zq1979@smu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jie Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Third Affiliated Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Jie Shen</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

